Amyloid aggregates play a major role in the development of
Alzheimer's disease. Targeting these aggregates by PET probes enables non-invasively the detection and quantification of
amyloid deposit distribution in human brains. Based on
benzothiazole core structure a series of
amyloid imaging agents were developed. Currently [(11)C]2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (
Pittsburgh Compound-B (PIB) is the most specific and widely used
amyloid imaging
ligand. But due to the short half life of (11)C, longer lived (18)F-labeled derivatives offer logistic advantages and higher contrast images. In this work, three different [(18)F]fluoroethoxy-substituted
benzothiazole derivatives ([(18)F]2-(4'-(methylamino)phenyl)-6-(2-fluoroethoxy)
benzothiazole, [(18)F]2-((2'-(2-fluoroethoxy)-4'-amino)phenyl)
benzothiazole and [(18)F]2-(3'-((2-fluoroethoxy)-4'-amino)phenyl)
benzothiazole) were synthesized via [(18)F]fluoroethylation. The latter two derivatives with fluoroethoxy-substitution on the aromatic amino group showed very low binding affinity for
amyloid aggregates. In contrast [(18)F]2-(4'-(methylamino)phenyl)-6-(2-fluoroethoxy)
benzothiazole with [(18)F]fluoroethoxy-substitution in 6-position showed excellent
amyloid imaging properties with respect to lipophilicity, brain entry and brain clearance in normal SCID mice,
amyloid plaque binding affinity and specificity.